BriaCell Therapeutics Corp.
News
BriaCell Therapeutics Announces Closing of $8.5 Million Offering
Globe Newswire PHILADELPHIA and VANCOUVER, British Columbia, Sept. 12, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ( BriaCell or the Company ), a clinical-stage...\n more…
BriaCell Therapeutics prices $8.5M equity offering
Seeking Alpha - Healthcare BriaCell Therapeutics prices $8.5M equity offering...\n more…
BriaCell Therapeutics Launches $8.5 Million Offering
TipRanks Financial Blog BriaCell Therapeutics (TSE:BCT) has released an update. BriaCell Therapeutics Corp., a biotech firm specializing in cancer immunotherapies, has announced an $8.5 mi...\n more…
BriaCell Therapeutics Announces $8.5 Million Offering
Globe Newswire Priced At-the-Market Under Nasdaq RulesPHILADELPHIA and VANCOUVER, British Columbia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ( BriaCell or...\n more…
Why Is Breast Cancer-Focused BriaCell Therapeutics Stock Trading Over 100% On Wednesday
Benzinga BriaCell Therapeutics stock rises on positive Phase 2 trial results showing improved survival in late-stage metastatic breast cancer patients treated with Bria-IMT and an immune checkpoint inhibitor.\n more…
BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer
Globe Newswire Median overall survival of 15.6 months in Phase 2 Bria-IMT study patients treated in combination with immune checkpoint inhibitorOS of 15.6 months compares favorably with 6.7-9.3 months reported for...\n more…